Imatinib Structural Formula (Image 3)
Imatinib Mesylate Tablet
Product Images NDC 0832-0532
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 0832-0532). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 Progression Free Survival (itt Principle) (Image 4)
This is a statistical report showing data related to progression, censoring, hazard ratio, log-rank test, and comparison between two arms in a study conducted over 72 months since randomization. The information in the text seems to be related to medical or clinical research, but specific details on the study are not clear from the provided text.*
Figure 2 Time To Progression To Ap Or Bc (itt Principle) (Image 5)
This text provides information on the treatment outcome of patients with Imatinib Mesylate who progressed to Accelerated Phase (AP) or Blast Crisis (BC). The hazard ratio and log-rank test results are also presented, indicating a statistically significant difference between the treatment groups. The data is presented over different time intervals since randomization, helping to understand the progression of the disease under study.*
Figure 3: Study 1 Recurrence-free Survival (itt Population) (Image 6)
Figure 4: Study 2 Recurrence-free Survival (itt Population) (Image 7)
Figure 5: Study 2 Overall Survival (itt Population) (Image 8)
Imatinib Mesylate Tablets 100 mg Bottle Label (Imt 100mg 90s Label)
This is a description of a medication called Imatinib Mesylate, which comes in a pack of 90 tablets with each tablet containing 100 mg of imatinib free base. The dosage and storage instructions are provided, along with the note that it is a prescription medication. It is recommended to keep the medication in a container defined by the USP regulations and to keep it out of reach of children. The product is distributed by Upsher-Smith Laboratories, LLC.*
Imatinib Mesylate Tablets 400 mg Bottle Label (Imt 400mg 30s Label)
This is a pharmaceutical label containing information about a medication. Each tablet contains 400 mg of the active ingredient. The storage instructions indicate to store the medicine between 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). The medication is formulated based on USP guidelines for room temperature and should be protected from moisture. It should be dispensed in a tight container as defined in the USP. The manufacturer is UPSHER-SMITH LABORATORIES located in Wape Grove, MN 55369. The copyright date on the label is 2024. The label states that the medication is for prescription use only and contains 30 tablets in total.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
